About

The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed, online journal of the Society for Immunotherapy of Cancer (SITC). The journal publishes articles on all aspects of tumor immunology and cancer immunotherapy and, in doing so, aims to enrich communication and advance scientific understanding among the many stakeholders in this rapidly evolving field. Topics of interest range widely across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

For information about Journal for ImmunoTherapy of Cancer Editor-in-Chief Pedro Romero and his editorial team, please refer to the Editorial Board page.

BMJ publishes JITC on behalf of the Society for Immunotherapy of Cancer.

Open access

Continuous

2013

Portico, LOCKSS

Web of Science Core Collection: Science Citation Index Expanded; MEDLINE (Index Medicus), PubMed Central, Scopus, DOAJ, Google Scholar

Single anonymised; the names of reviewers are hidden from the author

N/A

2051-1426

Acceptance rate: 23%

Speed Time to first decision without review: 5 days (median) Time to first decision with review: 39 days (median) Time from acceptance to publication: 31 days (median)

Impact Impact Factor (JCR): 12.485 Impact Factor rank : 25/245 (Oncology), 18/161 (Immunology) 5 Year Impact Factor: 13.892 Journal Citation Indicator: 1.97 Eigenfactor: 0.03885 Citescore: 14.3 Citescore rank: 25/360 Scimago Journal rank (SJR): 3.45

Reach Total content views: 1.12 million Total Altmetric mentions: 8,059

The impact that academic research has cannot be defined by one single metric. In 2013, BMJ signed the San Francisco Declaration on Research Assessment (DORA). We did this to show our support for using multiple measures and metrics to portray journals’ impact; moving away from the Impact Factor as a single measure. How we get these metrics

For all contact information please refer to the contact us page.

Please refer to the Instructions for authors.

Jim Cunningham jcunningham@cunnasso.com Tel: +1 201.767.4170 Fax: +1 201.767.8065 Information on rates

Mark Clifford Email: mclifford@bmj.com Information about advertising

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Its mission is to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.

BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.

The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.

BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.